{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:14:57Z","timestamp":1777965297555,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>Laser therapy has been proposed to improve the symptoms of genitourinary syndrome of menopause (GSM), especially in women who do not accept hormonal therapy or are at a high risk of complications if they undergo hormonal therapy. However, studies evaluating the effectiveness and safety of laser treatment for GSM have shown controversial results. Thus, we aimed to determine the efficacy and safety of laser therapy in post-menopausal women with GSM. We have developed a protocol according to the Preferred Reporting Items for Systematic Review and Meta-analysis Protocol using the population, intervention, comparison, outcome, and study design (PICOS) framework for post-menopausal women who have received no treatment, laser therapy, placebo, or vaginal estrogen for GSM. As per our protocol, randomized controlled trials and quasi-randomized trials, regardless of language of publication, will be searched in PubMed, Embase, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, and <jats:ext-link>clinicaltrials.gov<\/jats:ext-link>. Gray literature will be searched in Open Gray and Google Scholar. The reference lists will be scanned for additional trials, and the authors will be contacted if necessary. Outcome data reported in a trial registry, even when no published results were available, will be analyzed. The search will be performed using key terms, such as \u201cpost-menopausal women,\u201d \u201cmenopausal genitourinary syndrome,\u201d \u201cvulvovaginal atrophy,\u201d and \u201claser therapy.\u201d Two review authors will independently screen the titles and abstracts, while three others will independently evaluate the full text of each study to determine its eligibility for this systematic review (SR). Any disagreement will be resolved through discussion and consensus. Data extraction will be performed independently using a standardized data collection form. Clinical outcomes, including vaginal atrophy, vaginal pH, dryness, dyspareunia, itching, burning, dysuria, urinary frequency, urinary urgency, and urinary incontinence, will be systematically evaluated. We will not perform a separate search for adverse effects; instead, we will consider the adverse effects described in the included studies. Furthermore, we will summarize the effects of dichotomous outcomes as risk ratios with 95% confidence intervals. On the other hand, continuous outcomes will be summarized by expressing treatment effects as a mean difference with standard deviation or as a standardized mean difference when different scales were used to measure the same outcome. We will use the Cochrane Risk of Bias 2 tool for bias assessment and the Grading of Recommendations Assessment, Development and Evaluation approach to rate the overall certainty of evidence. Review Manager 5.3.5 will be used for quantitative data synthesis, subgroup analysis, sensitivity analysis, meta-regression, and risk of bias assessment. The SR findings will provide highly relevant evidence through the synthesis of well-designed and robust clinical trials on the effectiveness and safety of laser therapy in GSM. The Prospective Register of Systematic Reviews (PROSPERO) registration number (2021) of the SR is CRD42021253605.<\/jats:p>","DOI":"10.3389\/frph.2021.772690","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T06:45:26Z","timestamp":1635230726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Laser Therapy for the Treatment of Genitourinary Syndrome of Menopause: A Protocol for Systematic Review and Meta-Analysis of Clinical Trials"],"prefix":"10.3389","volume":"3","author":[{"given":"Lisieux de Lourdes Martins N\u00f3brega","family":"Pessoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayane Cristine Alves","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kleyton Santos","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Ferreira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Katherine","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Ney","family":"Cobucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e556","DOI":"10.1016\/j.clbc.2019.04.007","article-title":"The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis","volume":"19","author":"Jha","year":"2019","journal-title":"Clin Breast Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.maturitas.2017.06.029","article-title":"Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis","volume":"103","author":"Pitsouni","year":"2017","journal-title":"Maturitas."},{"key":"B3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11934-018-0831-y","article-title":"Laser therapy for genitourinary syndrome of menopause","volume":"19","author":"Rabley","year":"2018","journal-title":"Curr Urol Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas."},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.maturitas.2015.08.001","article-title":"Genitourinary syndrome of menopause and the use of laser therapy","volume":"82","author":"Hutchinson-Colas","year":"2015","journal-title":"Maturitas."},{"key":"B6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climacteric."},{"key":"B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/lsm.22637","article-title":"Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies","volume":"49","author":"Tadir","year":"2017","journal-title":"Lasers Surg Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00192-017-3282-y","article-title":"Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence","volume":"28","author":"Arunkalaivanan","year":"2017","journal-title":"Int Urogynecol J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/medicina55100615","article-title":"Vaginal health in menopausal women","volume":"55","author":"Alvisi","year":"2019","journal-title":"Medicina."},{"key":"B11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12955-021-01721-z","article-title":"Identification of the urogenital distress inventory-6 and the incontinence impact questionnaire-7 cutoff scores in urinary incontinent women","volume":"19","author":"Skorupska","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1590\/S0034-89102004000300015","article-title":"NR. Valida\u00e7\u00e3o para o portugu\u00eas do \u201cInternational Consultation on Incontinence Questionnaire - Short Form\u201d (ICIQ-SF)","volume":"38","author":"Tamanini","year":"2004","journal-title":"Rev Sa\u00fade P\u00fablica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/13697137.2018.1495705","article-title":"The menopause visual analogue scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition","volume":"21","author":"Dama","year":"2018","journal-title":"Climacteric."},{"key":"B14","first-page":"23","article-title":"An overactive bladder symptom and quality-of-life short form: development of the overactive bladder questionnaire short form (OAB-q SF)","author":"Coyne","year":"2004","journal-title":"34th Joint Meeting of the International Continence Society and the International UroGynecological Association"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1007\/s00192-020-04422-1","article-title":"Validation of the Thai version of the international consultation on incontinence questionnaire-female lower urinary tract symptoms (ICIQ-FLUTS)","volume":"31","author":"Chattrakulcha","year":"2020","journal-title":"Int Urogynecol J."},{"key":"B16","unstructured":"Chapter 8: assessing risk of bias in included studies\n            Higgins JPT AD\n            SterneJAC\n          Cochrane Handbook for Systematic Reviews of Interventions Version 5202017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. IntroductionGRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/GME.0000000000001428","article-title":"Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study","volume":"27","author":"Filippini","year":"2020","journal-title":"Menopause."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.urology.2020.09.012","article-title":"Update: the clinical role of vaginal lasers for the treatment of the genitourinary syndrome of menopause","volume":"151","author":"Mounir","year":"2021","journal-title":"Ambulatory."},{"key":"B20","unstructured":"Statement From FDA Commissioner Scott Gottlieb MD, on Efforts to Safeguard Women's Health From Deceptive Health Claims and Significant Risks Related to Devices Marketed for Use in Medical Procedures for \u201cVaginal Rejuvenation\u201d"},{"key":"B21","unstructured":"Fractional Laser Treatment of Vulvovaginal Atrophy U.S. Food and Drug Administration Clearance"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.772690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T06:45:50Z","timestamp":1635230750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2021.772690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":21,"alternative-id":["10.3389\/frph.2021.772690"],"URL":"https:\/\/doi.org\/10.3389\/frph.2021.772690","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"article-number":"772690"}}